Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации8435UnclassifiedEVALUATION OF THE EFFECTIVENESS OF DROSPIRENONE-CONTAINING COMBINED CONTRACEPTIVES IN THE TREATMENT OF PREMENSTRUAL SYNDROMEKarpovaDaria Vladimirovnadariakarpova2000@mail.ruhttps://orcid.org/0000-0002-3846-2011KhoperskayaOlga Viktorovna<p>Candidate of Medical Sciences, Assistant, Department of Obstetrics and Gynecology No. 2, N.N. Burdenko State Medical University</p>khoperskaya88@bk.ruhttps://orcid.org/0000-0003-4199-8156Voronezh State Medical University named after N.N. Burdenko2004202312S227291402202316042023Copyright © 2023, Karpova D., Khoperskaya O.V.2023<div id="KnM9nf"> <div id="tw-source"> <div id="tw-source-rmn-container" class="tw-ta-container F0azHf tw-nfl"> <pre class="tw-data-text tw-text-small tw-ta" dir="ltr" data-placeholder="">Premenstrual syndrome is a set of mental and physical symptoms that occur in the luteal phase of the menstrual cycle and lead to a decrease in the quality of life, performance and productivity of women. The prevalence of premenstrual symptoms varies by ethnicity, age, and social group, but the overall prevalence of premenstrual syndrome is about 80%. The aim of the study was to evaluate the effectiveness of drospirenone-containing combined contraceptives in the treatment of premenstrual syndrome.</pre> <pre class="tw-data-text tw-text-large tw-ta" dir="ltr" data-placeholder="Перевод"><span class="Y2IQFc" lang="en">The study group consisted of women of the early and optimal reproductive period (18-35 years old) who applied for an appointment at the antenatal clinic of the VGKP No. 1. The inclusion criteria for the study were the presence of symptoms of premenstrual syndrome according to a specially designed questionnaire, as well as the woman's reproductive age. The study involved 43 women voluntarily.<br /></span></pre> <pre id="tw-target-text" class="tw-data-text tw-text-large tw-ta" dir="ltr" data-placeholder="Перевод"><span class="Y2IQFc" lang="en">Patients who had symptoms of premenstrual syndrome were prescribed a drug that contains 3 mg of drospirenone and 20 g of ethinyl estradiol, which the women took on a 24/4 basis for 3 menstrual cycles. The study found that when taking hormonal contraceptives, the severity of symptoms decreased by an average of 46%. The study showed the high efficiency of drospirenone-containing contraceptive in the treatment of women with premenstrual syndrome.</span></pre> <p></p> </div> </div> </div>Premenstrual syndromehormonal contraceptionoral contraceptivesПредменструальный синдромгормональная контрацепцияоральные контрацептивы1.Ледина А. В., Прилепкая В.Н. Предменструальный синдром. К вопросу о клинико-диагностических критериях. // Фарматека. - 2012. - №12(245). - С. 13-17. [Ledina A.V., Prilepkaya V.N. Premenstrual syndrome. To the question of clinical diagnostic criteria. Pharmateka. 2012; 12(245): 13-17.]2.Wittchen H.U., Becker E., Lieb R. Et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002; 32(1): 119-132. http://doi.org/10.1017/s0033291701004925.3.Borenstein J.E., Dean B.B., Endicott J. Et al. Health and economic impact of the premenstrual syndrome. J Reprod Med. 2003; 48 (7): 515-524.4.Ледина А.В., Прилепская В.Н., Акимкин В.Г. Предменструальный синдром: распространенность и основные проявления (результаты эпидемиологического исследования) // Эпидемиология и вакцинопрофилактика. - 2014. - №2(75). - С. 66-71. [Ledina A.V., Prilepskaya V.N., Akimkin V.G. Premenstrual syndrome: prevalence and main manifestations (results of an epidemiological study). Epidemiology and vaccination. 2014; 2(75): 66-71.]5.Поздняк А. О. Возможности использования заместительной гормональной терапии с позиции современных международных исследований // Практическая медицина. - 2012. - №9(65). - С. 35-38. [Pozdnyak A. O. Possibilities of using hormone replacement therapy from the standpoint of modern international studies. Practical Medicine. 2012; 9 (65): 35-38.]6.Russell S., Wiles H. Improving combined contraceptive pill/oral contraceptives prescribing in general practice. BMJ Open Qual. 2017; 6(2): e000137. http://doi.org/10.1136/bmjoq-2017-000137.7.Kraus C., Hooper-Lane C. Are oral emergency contraceptives a safe and effective form of long-term birth control? J Fam Pract. 2017; 66(10): 632-634.8.Klipping C., Duijkers I., Mawet M. Et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021; 103(4): 213-221. http://doi.org/10.1016/j.contraception.2021.01.001.